Immunotherapy for bladder Ca: What urologists need to know
Peter Black, MD, discusses which patients are currently eligible for immunotherapy, how the indications are likely to expand, some of the common side effects of immunotherapy and their incidence, and the availability of tools to determine which patients are suitable candidates for treatment.
In the treatment of bladder cancer, the use of newer immunotherapy agents as second-line treatment and in patients who are ineligible for cisplatin-based chemotherapy is “the tip of the iceberg,” according to Peter Black, MD, of the University of British Columbia in Vancouver.
In the near future, look for these agents to be used earlier in the disease process, Dr. Black said.
In this video, Dr. Black discusses which patients are currently eligible for immunotherapy, how the indications are likely to expand, some of the common side effects of immunotherapy and their incidence, and the availability of tools to determine which patients are suitable candidates for treatment.
Dr. Black is a consultant/adviser to GenomeDx Biosciences, Janssen, Astellas, Amgen, Sitka, AbbVie, Bristol Myers Squibb, Bayer, Biosyent, Sanofi, Urogen, and Roche/Genentech. He conducts laboratory research for iProgen.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
